Clear market notes built around the JSE, the rand, and what matters locally.

2026-08-06 12:30 • The Motley Fool Positive Axe Cap view: Selective

Arcutis Biotherapeutics CEO Todd Watanabe sold 4,375 shares for $114,275 on August 3, 2026, to cover tax withholding obligations on vesting restricted stock units. The sale is non-discretionary and does not signal a change in management sentiment. Meanwhile, Arcutis reported strong Q2 2026 results with its flagship product Zoryve generating $129.9 million in revenue (59% growth) and the company achieving profitability with $15 million net income. The company raised full-year guidance to $525-540 million and received FDA approval to expand Zoryve's indication to treat plaque psoriasis in children as young as age 2.

Axe note: Robust Q2 growth and profitability from Arcutis impress, but the South African market should watch USD/ZAR instead.

2026-08-06 12:18 • The Motley Fool Positive Axe Cap view: Selective

The ARK Innovation ETF (ARKK) remains a volatile but potentially rewarding investment option despite mixed recent performance. The fund focuses on emerging technologies including AI, robotics, genomics, and autonomous vehicles, offering low correlation with the S&P 500 and unique diversification benefits. While it may underperform for extended periods, its long-term potential and distinct portfolio composition make it worthy of consideration as a modest allocation in diversified portfolios.

Axe note: Cathie Wood's ARKK fund still offers unique tech exposure despite years of tough performance.

2026-08-06 12:05 • The Motley Fool Positive Axe Cap view: Selective

Nuclear energy is experiencing a resurgence driven by AI data centers' power demands. The VanEck Uranium and Nuclear ETF (NLR) is recommended as a diversified way to gain exposure to the nuclear industry, holding both established uranium mining companies and emerging small modular reactor developers. While growth potential is strong, many nuclear companies remain pre-revenue and speculative.

Axe note: Nuclear energy's revival is real, but South African investors should tread carefully, favouring diversified exposure over single stocks.